Bristol Myers Squibb is expanding a partnership with oncology organization Sarah Cannon Research Institute, tapping into SCRI ...
BMS and J&J first linked together in 2018 to develop factor X1a inhibitors as anti-coagulants. The three Phase III Librexia ...
The TV ad will run through Nov. 16 across major cable channels, including CNN, Fox News and ESPN, a BMS spokesperson told ...
In an era where energy efficiency and sustainability are essential, BMS have emerged as critical components in industrial and ...
On the heels of a clinical setback for Bristol Myers Squibb’s schizophrenia newcomer Cobenfy, the New Jersey pharma is serving up mixed results for the first three months of the year. Still, even as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback